Novo Nordis Short

19. Sept.

Shorting Novo Nordisk may be considered due to potential overvaluation, rising competition in diabetes and obesity markets, supply chain challenges, and risks from patent expirations. Regulatory hurdles, slower demand in key regions, and macroeconomic factors like healthcare budgets and inflation could further impact growth. However, thorough analysis is essential, as shorting carries high risk.

26. Sept.

Kommentar

at the neckline, could have a bit of oscillation, but once break down $120, heading to the target $100.

29. Sept.

Kommentar

Neckline broke, any small fundamental issue would incur the acceleration to the target

25. Okt.

Kommentar

will close half of my put position when it hits below $110 prior to the earning, that would give the trade a 75% profit